• 1
    World Health Organization. Global Alert and Response (GAR): Pandemic (H1N1) 2009 – update 112. Available at (Accessed June 3 2011).
  • 2
    Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med 2009; 361:19351944.
  • 3
    Yu H, Feng Z, Uyeki TM et al. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis 2011; 52:457465.
  • 4
    Yang P, Deng Y, Pang X et al. Severe, critical and fatal cases of 2009 H1N1 influenza in China. J Infect 2010; 61:277283.
  • 5
    World Health Organization. H1N1 in post-pandemic period. Available at (Accessed June 3 2011).
  • 6
    Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; 375:11001108.
  • 7
    Chen MI, Lee VJ, Lim WY et al. 2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA 2010; 303:13831391.
  • 8
    Tian LL, Shi WX, Ying D et al. Serologic survey of pandemic influenza A (H1N1 2009) in Beijing, China. Prev Med 2010; 52:7174.
  • 9
    Deng Y, Pang XH, Yang P et al. Serological survey of 2009 H1N1 influenza in residents of Beijing, China. Epidemiol Infect 2010; 139:5258.
  • 10
    Lee VJ, Yap J, Cook AR et al. Effectiveness of public health measures in mitigating pandemic influenza spread: a prospective sero-epidemiological cohort study. J Infect Dis 2010; 202:13191326.
  • 11
    Zhu FC, Wang H, Fang HH et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:24142423.
  • 12
    Clark TW, Pareek M, Hoschler K et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:24242435.
  • 13
    Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2009; 375:4148.
  • 14
    Liang XF, Wang HQ, Wang JZ et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2009; 375:5666.
  • 15
    Wu J, Xu F, Lu L et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2010; 363:24162423.
  • 16
    Ortqvist A, Berggren I, Insulander M, de Jong B, Svenungsson B. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. Clin Infect Dis 2011; 52:12031211.
  • 17
    Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F et al. Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case–control study. Vaccine 2010; 28:74607467.
  • 18
    Wichmann O, Stocker P, Poggensee G et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009–2010. Euro Surveill 2010; 15:pii: 19561.
  • 19
    World Health Organization. Recommended viruses for influenza vaccines for use in the 2010–2011 northern hemisphere influenza season. Available at (Accessed June 3 2011).
  • 20
    Yang P, Duan W, Lv M et al. Review of an influenza surveillance system, Beijing, People’s Republic of China. Emerg Infect Dis 2009; 15:16031608.
  • 21
    Mehr DR, Binder EF, Kruse RL et al. Predicting mortality in nursing home residents with lower respiratory tract infection: The Missouri LRI Study. JAMA 2001; 286:24272436.
  • 22
    Wang M, Yuan J, Li T et al. Antibody dynamics of 2009 influenza A (H1N1) virus in infected patients and vaccinated people in China. PLoS ONE 2011; 6:e16809.
  • 23
    Nguyen TV, Yuan L, Azevedo MS et al. High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen. Clin Vaccine Immunol 2006; 13:475485.
  • 24
    Co MD, Orphin L, Cruz J et al. Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. Vaccine 2008; 26:19901998.
  • 25
    Crowe JE Jr. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin Infect Dis 2001; 33:17201727.
  • 26
    Crowe JE Jr, Firestone CY, Murphy BR. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 2001; 167:39103918.
  • 27
    Rubin GJ, Amlot R, Page L, Wessely S. Public perceptions, anxiety, and behaviour change in relation to the swine flu outbreak: cross sectional telephone survey. BMJ 2009; 339:b2651.
  • 28
    Pebody R, Hardelid P, Fleming D et al. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Euro Surveill 2011; 16:pii: 19791.
  • 29
    Castilla J, Moran J, Martinez-Artola V et al. Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis. Euro Surveill 2011; 16:pii: 19799.
  • 30
    Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009; 199:14351441.
  • 31
    Xu C, Bai T, Iuliano AD et al. The seroprevalence of pandemic influenza H1N1 (2009) virus in China. PLoS ONE 2011; 6:e17919.
  • 32
    Zeman AM, Holmes TH, Stamatis S et al. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J 2007; 26:107115.
  • 33
    Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, Murasko DM. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 1999; 17:8294.
  • 34
    Guthrie T, Hobbs CG, Davenport V, Horton RE, Heyderman RS, Williams NA. Parenteral influenza vaccination influences mucosal and systemic T cell-mediated immunity in healthy adults. J Infect Dis 2004; 190:19271935.
  • 35
    Murasko DM, Bernstein ED, Gardner EM et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002; 37:427439.